Podcast Episodes
Back to SearchShared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC
Episode 24
Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with pati…
8 months ago
“Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions
Episode 21
Tackling central nervous system (CNS) disease in EGFR-mutated non-small cell lung cancer “is a huge problem, both from a quality-of-life perspective …
8 months ago
Second-Line Options in EGFR-Mutated NSCLC: What’s the Right Sequence?
Episode 22
8 months ago
“Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC
Episode 23
With multiple regimens available for advanced EGFRm NSCLC, selecting the best regimen for an individual patient is key. Jorge Nieva, MD, tells host A…
8 months ago
As Terminal Patients Live Longer, How Can Oncologists Help Them Cope With Uncertainty?
Episode 20
Progress in cancer care means that millions of patients are living longer lives, albeit without hope of a cure. What role can oncologists and other p…
8 months ago
Should Patients With Cancer Receive mRNA Vaccines Alongside Immunotherapy?
Episode 19
A recent study found a link between mRNA vaccination and improved cancer immunotherapy response. The preclinical data demonstrated impressive results…
9 months ago
Big News From ESMO 2025 Changes Practice in Bladder Cancer
Episode 18
Survival data from the KEYNOTE-905 trial and insights into the use of circulating tumor DNA to guide treatment decisions from IMvigor011 made big wav…
9 months, 3 weeks ago
Big Changes in AML Care as Targeted Therapy Options Expand
Episode 17
Options for the treatment of acute myeloid leukemia (AML) are rapidly expanding, says Amir Fathi, MD, associate professor of medicine at Harvard Medi…
10 months ago
Artificial Sweetener May Impair Cancer Immunotherapy, Raising Broader Questions
Episode 16
The artificial sweetener sucralose may impair the efficacy of cancer immunotherapy, according to a recent study published in Science. Although furthe…
10 months, 4 weeks ago
“Massive Advance” Changes the Chessboard in EGFR-Mutated Metastatic NSCLC
Episode 15
New survival data from the FLAURA2 and MARIPOSA trials represent “a massive advance for our patients” in terms of frontline treatment for EGFR-mutate…
11 months ago